Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment.
Levi & Korsinsky is investigating potential securities law violations at Exelixis, including whether the Company adequately disclosed the condition of its neuroendocrine-tumor commercial ramp before the guidance reduction. On the May 5, 2026 first quarter earnings call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance." That guidance was subsequently lowered.
Shareholders who lost money on EXEL are encouraged to contact the firm about their losses . You may also reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the EXEL Investigation
Q: What is the EXEL investigation about? A: A securities investigation is pending concerning Exelixis (NASDAQ: EXEL) regarding potentially materially false or misleading statements. Shares declined after the Company reported Q2 revenue of approximately $628.7 million, below consensus, and lowered its full-year 2026 revenue guidance citing a slower-than-expected neuroendocrine-tumor ramp.
Q: Who is eligible to participate in the EXEL investigation? A: Investors who purchased EXEL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Exelixis made materially false or misleading statements regarding CABOMETYX commercial performance, the neuroendocrine-tumor business, and the reiteration of full-year 2026 financial guidance.
Q: What do EXEL investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my EXEL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EXEL and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260812194921/en/
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
/The%20front%20of%20a%20Rocket%20Lab%20corporate%20office%20by%20Emagnetic%20via%20Shutterstock.jpg)
